French researchers identified a specific phenotype along with predictive factors.
Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg
Emerging Agents in the Treatment of Rheumatic Diseases
FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis
Febuxostat Use Among Gout Asian Patients Linked to Increased Cardiovascular Risk